Physician profile
Daniel L Wohl
NPI 1275588303
$1,693.23
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $85.06 · 2021: $260 · 2022: $16.36 · 2023: $286 · 2024: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $337.08 | 2019-2023 | Dupixent |
| Integra Lifesciences Corporation | $285.12 | 2024 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Genzyme Corporation | $233.23 | 2021-2024 | |
| Smith+Nephew, INC. | $226.44 | 2019-2021 | |
| Medtronic, INC. | $110.85 | 2023-2024 | Nim Vital, Fusion |
| Stryker Corporation | $98.64 | 2019 | |
| Edwards Lifesciences Corporation | $96.36 | 2021 | |
| Glaxosmithkline, LLC. | $93.24 | 2024 | Nucala |
| Alk-Abello, INC | $69.21 | 2020-2022 | |
| Acclarent, INC | $67.12 | 2019 | |
| Preceptis Medical, INC. | $55.84 | 2019 | |
| Photonicare INC | $20.10 | 2023 | Otosight Middle Ear Scope |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.